How long will investors still hold out patience for Nike after two years of a “stale innovation pipeline?”
Analyst bumps up price target on QDEL on back of “sweetened” deal to acquire Alere’s BNP Assay segment.
Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.
One top analyst raises price target on Oracle; another analyst believes the worst is now over for the giant.
Analyst introduces new expectations for Apple to sell 233 million iPhones in 2019.
However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.
AMD has good odds for reward; Nvidia’s GPU game is strong; but Intel’s PC segment is the real gamble.
PTN focusing on entering the EU market through partnerships, says analyst.
Synergy protects “financial health” without the sacrifice of extra pressure on share price, says Canaccord.
The Risk/Reward Factor of Lulu’s EPS Stalling Growth Does Not Look Too Good, Fears Analyst